Novel approaches to anticonvulsant drug discovery

Bibliography

• Gross RA. A brief history of epilepsy and its therapy in the Western Hemisphere. Epilepsy Res 1992;12:65-74
   PubMed Web of Science ®Google Scholar
• Magiorkinis E, Sidiropoulou K, Diamantis A. Hallmarks in the history of epilepsy: epilepsy in antiquity. Epilepsy Behav 2010;17:103-8
   PubMed Web of Science ®Google Scholar
• Foyaca-Sibat H. Novel aspects on epilepsy. InTech; Rijeka: Croatia: 2011
   Google Scholar
• Longrigg J. Epilepsy in ancient Greek medicine-the vital step. Seizure 2000;9:12-21
   PubMed Web of Science ®Google Scholar
• Fatović-Ferencić S, Dürrigl MA. The sacred disease and its patron saint. Epilepsy Behav 2001;2:370-3
   PubMed Web of Science ®Google Scholar
• Reynolds EH, Rodin E. The clinical concept of epilepsy. Epilepsia 2009;50(Suppl 3):2-7
   PubMedGoogle Scholar
• Bladin PF, Eadie MJ. A disease once sacred: a history of the medical understanding of epilepsy. JohnLibbey; Eastleigh: England: 2001
   Google Scholar
• Eadie MJ. Sir Charles Locock and potassium bromide. J R Coll Physicians Edinb 2012;42:274-9
   PubMedGoogle Scholar
• Wieser HG. Treatment of epilepsy: where are we today?. [Article in German]. Praxis (Bern 1994) 1996;85:74-9
   PubMedGoogle Scholar
• Yasiry Z, Shorvon SD. How phenobarbital revolutionized epilepsy therapy: the story of phenobarbital therapy in epilepsy in the last 100 years. Epilepsia 2012;53(Suppl 8):26-39
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure 2010;19:650-5
   PubMed Web of Science ®Google Scholar
• Putnam TJ, Merritt HH. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science 1937;85:525-6
   PubMedGoogle Scholar
• Glazko AJ. Discovery of phenytoin. Ther Drug Monit 1986;8:490-7
   PubMed Web of Science ®Google Scholar
• Young RS, Alger PM, Bauer L, Lauderbaugh D. A randomized, double-blind, crossover study of phenobarbital and mephobarbital. J Child Neurol 1986;1:361-3
   PubMed Web of Science ®Google Scholar
• Aiken SP, Brown WM. Treatment of epilepsy: existing therapies and future developments. Front Biosci 2000;5:E124-52
   PubMed Web of Science ®Google Scholar
• Gallagher BB, Baumel IP, Woodbury SG, Dimicco JA. Clinical evaluation of eterobarb, a new anticonvulsant drug. Neurology 1975;25:399-404
   PubMed Web of Science ®Google Scholar
• Bogue JY, Carrington HC. The evaluation of “mysoline”, a new anticonvulsant drug. Br J Pharmacol Chemother 1953;8:230-6
   PubMed Web of Science ®Google Scholar
• Bialer M. How did phenobarbital's chemical structure affect the development of subsequent antiepileptic drugs (AEDs)? Epilepsia 2012;53(Suppl(8):3-11
   PubMedGoogle Scholar
• Heathfield KW, Jewesbury EC. Treatment of petit mal with ethosuximide. Br Med J 1961;2:565-7
   PubMed Web of Science ®Google Scholar
• Schindler W. 5H-Dibenz[b,f]azepines. US2948718; 1960
   Google Scholar
• Schatzberg A, Nemeroff CB. Textbook of psychopharmacology. American Psychiatric Press; Washington DC: 1995
   Google Scholar
• Meunier H, Carraz G, Neunier Y, et al. Pharmacodynamic properties of N-dipropylacetic acid. [Article in French]. Therapie 1963;18:435-8
   PubMedGoogle Scholar
• Henry TR. The history of valproate in clinical neuroscience. Psychopharmacol Bull 2003;37(Suppl 2):5-16
   PubMedGoogle Scholar
• Carraz G, Darbon Lebreton S, Beriel H. Pharmacodynamic properties of 2,2-dipropylacetic acid and its derivatives. 4th report: 2,2 dipropylacetamide. [Article in French]. Therapie 1964;19:468-76
   PubMedGoogle Scholar
• Chapman A, Keane PE, Meldrum BS, et al. Mechanism of anticonvulsant action of valproate. Prog Neurobiol 1982;19:315-59
   PubMed Web of Science ®Google Scholar
• Lason W, Dudra-Jastrzebska M, Rejdak K, Czuczwar SJ. Basic mechanism of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update. Pharmacol Rep 2011;63:271-92
   PubMed Web of Science ®Google Scholar
• Keck PE, McElroy SL. Clinical pharmacodynamics and pharmacokinetics of antimanic and mood-stabilizing medications. J Clin Psychiatry 2002;63(Suppl(4):3-11
   PubMedGoogle Scholar
• Smith M, Wilcox KS, White HS. Discovery of antiepileptic drugs. Neurotherapeutics 2007;4:12-17
   PubMed Web of Science ®Google Scholar
• Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5:3-14
   PubMed Web of Science ®Google Scholar
• Swinyard EA, Sofia RD, Kupferberg HJ. Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats. Epilepsia 1986;27:27-34
   PubMed Web of Science ®Google Scholar
• Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol 1994;17:389-402
   PubMed Web of Science ®Google Scholar
• Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res 2000;39:47-55
   PubMed Web of Science ®Google Scholar
• De Sarro G, Ongini E, Bertorelli R, et al. Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol 1994;262:11-19
   PubMed Web of Science ®Google Scholar
• Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acidA receptors. Ann Neurol 1994;35:229-34
   PubMed Web of Science ®Google Scholar
• Morris GL. Gabapentin. Epilepsia 1999;40(Suppl 5):S63-70
   PubMedGoogle Scholar
• Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996;37(Suppl 6):S4-11
   PubMedGoogle Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the fourth Eilat conference (EILAT IV). Epilepsy Res 1999;34:1-41
   PubMed Web of Science ®Google Scholar
• Gee NS, Brown JP, Dissanayake VU, et al. The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel. J Biol Chem 1996;271:5768-76
   PubMed Web of Science ®Google Scholar
• Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(Suppl(1):S2-9
   PubMedGoogle Scholar
• Stefani A, Spadoni F, Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy? Epilepsia 1997;38:959-65
   PubMed Web of Science ®Google Scholar
• Macdonald RL, Greenfield LJ Jr. Mechanisms of action of new antiepileptic drugs. Curr Opin Neurol 1997;10:121-8
   PubMed Web of Science ®Google Scholar
• Sachdeo RC. Topiramate. Clinical profile in epilepsy. Clin Pharmacokinet 1998;34:335-4
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51:31-71
   PubMed Web of Science ®Google Scholar
• Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998;55:437-60
   PubMed Web of Science ®Google Scholar
• Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41:1364-74
   PubMed Web of Science ®Google Scholar
• Meldrum BS. Gamma-aminobutyric acid and the search for new anticonvulsant drugs. Lancet 1978;2:304-6
   PubMed Web of Science ®Google Scholar
• Schechter PJ, Tranier Y, Jung MJ, Böhlen P. Audiogenic seizure protection by elevated brain GABA concentration in mice: effects of gamma-acetylenic gaba and gamma-vinyl GABA, two irreversible GABA-T inhibitors. Eur J Pharmacol 1977;45:319-28
   PubMed Web of Science ®Google Scholar
• Kleinrok Z, Czuczwar SJ, Kozicka M. Effect of dopaminergic and GABA-ergic drugs given alone or in combination on the anticonvulsant action of phenobarbital and diphenylhydantoin in the electroshock test in mice. Epilepsia 1980;21:519-29
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ. Effect of combined treatment with dopaminergic and GABA-ergic drugs on the threshold for maximal electroconvulsions in mice. Pol J Pharmacol Pharm 1981;33:25-35
   PubMedGoogle Scholar
• Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs 2001;15:339-50
   PubMed Web of Science ®Google Scholar
• Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011;20:359-68
   PubMed Web of Science ®Google Scholar
• Beyenburg S, Bauer J, Reuber M. New drugs for the treatment of epilepsy: a practical approach. Postgrad Med J 2004;80:581-7
   PubMed Web of Science ®Google Scholar
• Stępień KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012;64:1011-19
   PubMed Web of Science ®Google Scholar
• Löscher W, Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma. Epilepsia 2011;52:657-78
   PubMed Web of Science ®Google Scholar
• Brandt C, Gastens AM, Sun MZ, et al. Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 2006;51:789-804
   PubMed Web of Science ®Google Scholar
• Bolanos AR, Sarkisian M, Yang Y, et al. Comparison of valproate and phenobarbital treatment after status epilepticus in rats. Neurology 1998;51:41-8
   PubMed Web of Science ®Google Scholar
• Rigoulot MA, Koning E, Ferrandon A, Nehlig A. Neuroprotective properties of topiramate in the lithium – pilocarpine model of epilepsy. J Pharmacol Exp Ther 2004;308:787-95
   PubMed Web of Science ®Google Scholar
• Pitkanen A, Kharatishvili I, Narkilahti S, et al. Administration of diazepam during status epilepticus reduces development and severity of epilepsy in rat. Epilepsy Res 2005;63:27-42
   PubMed Web of Science ®Google Scholar
• Chroscinska-Krawczyk M, Jargiello-Baszak M, Walek M, et al. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol Rep 2011;63:12-18
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Gasior M, Janusz W, et al. Influence of different methylxanthines on the anticonvulsant action of common antiepileptic drugs in mice. Epilepsia 1990;31:318-23
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Kleinrok Z. Modulation of the protective efficacy of common antiepileptic drugs by xanthine derivatives: implications for the clinical use of xanthines in epileptic patients. Pharmacol Res 1990;22:661-5
   PubMed Web of Science ®Google Scholar
• Dworetzky BA, Bromfield EB, Townsend MK, Kang JH. A prospective study of smoking, caffeine, and alcohol as risk factors for seizures or epilepsy in young adult women: data from the Nurses' Health Study II. Epilepsia 2010;51:198-205
   PubMed Web of Science ®Google Scholar
• Kaufman KR, Sachdeo RC. Caffeinated beverages and decreased seizure control. Seizure 2003;12:519-21
   PubMed Web of Science ®Google Scholar
• Bonilha L, Li LM. Heavy coffee drinking and epilepsy. Seizure 2004;13:284-5
   PubMed Web of Science ®Google Scholar
• Gilbert RM, Marshman JA, Schwieder M, Berg R. Caffeine content of beverages as consumed. Can Med Assoc J 1976;114:205-8
   PubMed Web of Science ®Google Scholar
• Smith JM, Pearson S, Marks V. Plasma caffeine concentration in outpatients. Lancet 1982;2:985-6
   PubMed Web of Science ®Google Scholar
• Lopez-Garcia E, Guallar-Castillon P, Leon-Muñoz L, et al. Coffee consumption and health-related quality of life. Clin Nutr 2013; published online 13 April 2013; doi: 10.1016/j.clnu.2013.04.004
   Web of Science ®Google Scholar
• Czuczwar M, Kis J, Czuczwar P, et al. Nicotine diminishes anticonvulsant activity of antiepileptic drugs in mice. Pol J Pharmacol 2003;55:799-802
   PubMedGoogle Scholar
• Sood N, Sahai AK, Medhi B, Chakrabarti A. Dose-finding study with nicotine as a proconvulsant agent in PTZ-induced seizure model in mice. J Biomed Sci 2008;15:755-65
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Kaplanski J, Swiderska-Dziewit G, et al. Pharmacodynamic interactions between antiepileptic drugs: preclinical data based on isobolography. Expert Opin Drug Metab Toxicol 2009;5:131-6
   PubMed Web of Science ®Google Scholar
• Stephen LJ, Brodie MJ. Seizure freedom with more than one antiepileptic drug. Seizure 2002;11:349-51
   PubMed Web of Science ®Google Scholar
• Merritt HH, Putnam TJ. Landmark article Sept 17, 1938: sodium diphenyl hydantoinate in the treatment of convulsive disorders. By H. Houston Merritt and Tracy J. Putnam. JAMA 1984;251:1062-7
   PubMed Web of Science ®Google Scholar
• Friedlander WJ. Putnam, Merritt, and the discovery of Dilantin. Epilepsia 1986;27(Suppl(3):S1-20
   PubMedGoogle Scholar
• Borowicz KK, Piskorska B, Kimber-Trojnar Z, et al. Is there any future for felbamate treatment? Pol J Pharmacol 2004;56:289-94
   PubMedGoogle Scholar
• Luszczki JJ. Third-generation antiepileptic drugs: mechanisms of action, pharmacokinetics and interactions. Pharmacol Rep 2009;61:197-216
   PubMed Web of Science ®Google Scholar
• Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behav 2004;5:627-35
   PubMed Web of Science ®Google Scholar
• Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin Investig Drugs 2006;15:637-47
   PubMed Web of Science ®Google Scholar
• Freidel M, Krause E, Kuhn K, et al. Oxcarbazepine in the treatment of epilepsy. [Article in German]. Fortschr Neurol Psychiatr 2007;75:100-6
   PubMed Web of Science ®Google Scholar
• Trojnar MK, Wierzchowska-Cioch E, Krzyzanowski M, et al. New generation of valproic acid. Pol J Pharmacol 2004;56:283-8
   PubMedGoogle Scholar
• Botros S, Khalil NA, Naguib BH, El-Dash Y. Synthesis and anticonvulsant activity of new phenytoin derivatives. Eur J Med Chem 2013;60:57-63
   PubMed Web of Science ®Google Scholar
• Drabczynska A, Yuzienko O, Köse M, et al. Synthesis and biological activity of tricyclic cycloalkilimidazo-, pyrimido- and diazepinopurinediones. Eur J Med Chem 2011;46:3590-607
   PubMed Web of Science ®Google Scholar
• Szkaradek N, Gunia A, Waszkielewicz AM, et al. Anticonvulsant evaluation of aminoalkanol derivatives of 2- and 4-methylxanthone. Bioorg Med Chem 2013;21:1190-8
   PubMed Web of Science ®Google Scholar
• Amir M, Ali I, Hassan MZ. Design and synthesis of some new quinazolin-4-(3H)-ones as anticonvulsant and antidepressant agents. Arch Pharm Res 2013;36:61-8
   PubMed Web of Science ®Google Scholar
• Plech T, Luszczki JJ, Wujec M, et al. Synthesis, characterization and preliminary anticonvulsant evaluation of some 4-alkyl-1,2,4-triazoles. Eur J Med Chem 2013;60:208-15
   PubMed Web of Science ®Google Scholar
• Luszczki JJ, Kominek M, Florek-Luszczki M, et al. Influence of N-hydroxymethyl-p-isopropoxyphenylsuccinimide on the anticonvulsant action of different classical antiepileptic drugs in the mouse maximal electroshock-induced seizure model. Epilepsy Res 2012;100:27-36
   PubMed Web of Science ®Google Scholar
• Löscher W. New visons in the pharmacology of anticonvulsion. Eur J Pharmacol 1998;342:1-13
   PubMed Web of Science ®Google Scholar
• Urbanska E, Czuczwar SJ, Kleinrok Z, Turski WA. Excitatory amino acids in epilepsy. Restor Neurol Neurosci 1998;13:25-39
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Swiader M, Kuzniar H, et al. LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol 1998;359:103-9
   PubMed Web of Science ®Google Scholar
• Zaccara G, Giovanelli F, Cincotta M, Iudice A. AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel. Expert Rev Neurother 2013;13:647-55
   PubMed Web of Science ®Google Scholar
• Simonato M, Löscher W, Cole AJ, et al. Finding a better drug for epilepsy: preclinical screening strategies and experimental trial design. Epilepsia 2012;53:1860-7
   PubMed Web of Science ®Google Scholar
• Acharya MM, Hattiangady B, Shetty AK. Progress in neuroprotective strategies for preventing epilepsy. Prog Neurobiol 2008;84:363-404
   PubMed Web of Science ®Google Scholar
• Hartman AL, Lyle M, Rogawski MA, Gasior M. Efficacy of the ketogenic diet in the 6-Hz seizure test. Epilepsia 2008;49:334-9
   PubMed Web of Science ®Google Scholar
• Thavendiranathan P, Chow C, Cunnane S, Burnham WM. The effect of the ‘classic' ketogenic diet on animal seizure models. Brain Res 2003;959:206-13
   PubMed Web of Science ®Google Scholar
• Cross JH, Mclellan A, Neal EG, et al. The ketogenic diet in childhood epilepsy: where are we now? Arch Dis Child 2010;95:550-3
   PubMed Web of Science ®Google Scholar
• Dhamija R, Eckert S, Wirrell E. Ketogenic diet. Can J Neurol Sci 2013;40:158-67
   PubMed Web of Science ®Google Scholar
• Todorova MT, Tandon P, Madore RA, et al. The ketogenic diet inhibits epileptogenesis in EL mice: a genetic model for idiopathic epilepsy. Epilepsia 2000;41:933-40
   PubMed Web of Science ®Google Scholar
• Hansen SL, Nielsen AH, Knudsen KE, et al. Ketogenic diet is antiepileptogenic in pentylenetetrazole kindled mice and decrease levels of N-acylethanolamines in hippocampus. Meurochem Int 2009;54:199-204
   PubMed Web of Science ®Google Scholar
• Linard B, Ferrnandon A, Koning E, et al. Ketogenic diet exhibits neuroprotective effects in hippocampus but fails to prevent epileptogenesis in the lithium-pilocarpine model of mesial temporal lobe epilepsy in adult rats. Epilepsia 2010;51:1829-36
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Turski L, Turski W, Kleinrok Z. Effects of some antiepileptic drugs in pentetrazol-induced convulsions in mice lesioned with kainic acid. Epilepsia 1981;22:407-14
   PubMed Web of Science ®Google Scholar
• Czuczwar SJ, Turski L, Kleinrok Z. Anticonvulsant action of phenobarbital, diazepam, carbamazepine, and diphenylhydantoin in the electroshock test in mice after lesion of hippocampal pyramidal cells with intracerebroventricular kainic acid. Epilepsia 1982;23:377-82
   PubMed Web of Science ®Google Scholar
• Margineanu DG. Systems biology impact on antiepileptic drug discovery. Epilepsy Res 2012;98:104-15
   PubMed Web of Science ®Google Scholar
• Wu Z, Xu Q, Zhang L, et al. Protective effect of reservatrol against kainate-induced temporal lobe epilepsy in rats. Neurochem Res 2009;34:1393-400
   PubMed Web of Science ®Google Scholar
• Pitkänen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol 2011;10:173-86
   PubMed Web of Science ®Google Scholar
• Kwon YS, Pineda E, Auvin S, et al. Neuroprotective and antiepileptogenic effects of combination of anti-inflammatory drugs in the immature brain. J Neuroinflammation 2013;10:30
   PubMed Web of Science ®Google Scholar
• Immonen R, Kharatishvili I, Gröhn O, Pitkanen A. MRI biomarkers for post-traumatic epileptogenesis. J Neurotrauma 2013;30:1305-9
   PubMed Web of Science ®Google Scholar